People in the News

Apr 10, 2018

Karen Gripp, Peter Krawitz

FDNA has appointed Karen Gripp as CMO and Peter Krawitz as chief data science officer. The maker of the Face2Gene suite of next-generation phenotyping (NGP) applications said in a statement that their combined clinical, research, and development experience "will elevate the use and proven success of NGP technologies that capture, structure, and interpret complex physiological information." Gripp is chief of medical genetics at the AI duPont Hospital for Children and a professor of pediatrics at the Sidney Kimmel Medical College at Thomas Jefferson University. Krawitz is director of the Institute for Genomic Statistics and Bioinformatics at the University of Bonn in Germany and has been working with FDNA on a study called Prioritization of Exome Data By Image Analysis, or PEDIA, to determine the impact of phenotype and facial analysis on molecular interpretation.

Apr 10, 2018

Matthew Strobeck

Quidel has appointed Matthew Strobeck, managing partner of Birchview Capital, to the company's board of directors after increasing the size of its board from seven to eight members. Strobeck was previously with Westfield Capital Management and currently serves on the boards of Accelerate Diagnostics and Biodesix.

Apr 10, 2018

Dirk Ehlers

Centogene has appointed Dirk Ehlers its chief operating officer and president of the diagnostics division. He joins the company from Hill-Rom Holdings where he was senior vice president and president of the sugical solutions division and served on the Group Executive Team. Before that, he was CEO of Eppendorf, and he has held management positions at Roche, Fresenius Kabi, Olympus Optical, and Evotec.

Apr 09, 2018

Rolland Carlson

Immunexpress announced today that it has appointed Rolland Carlson as CEO. Carlson previously served as president and CEO of WaferGen Biosystems. Before WaferGen, Carlson was president and CEO of Asurgen, where he established company operations and developed 17 clinical products and services. Prior to Asuragen, Carlson held senior positions at Abbott Laboratories over a 20-year period. 

Apr 09, 2018

Tom Lindsay

Genedrive has appointed Tom Lindsay as a non-executive director, effective immediately. Lindsay most recently was at Alere, where he held roles including president of Africa, president of commercial operations in Africa, and business development director for Africa, before he retired in 2017. Prior to Alere, he held senior commercial roles at Trinity Biotech. 

Apr 09, 2018

Paul Billings

Natera has appointed Paul Billings as its chief medical officer and senior vice president of medical affairs, where he will help lead efforts across the firm's reproductive health, oncology, and new emerging businesses. Billings is a board-certified internist and clinical geneticist with more than 30 years of experience in genomics and molecular medicine, having held academic and research appointments at Harvard University, UC San Francisco, Stanford University, and UC Berkeley.

Prior to joining Natera, Billings was chief medical officer of Life Technologies, consulting CMO of the genetic sciences division of Thermo Fisher Scientific, and senior physician at Laboratory Corporation of America. He has served on the scientific advisory board of the US Food and Drug Administration, the genomic medicine advisory committee at the Department of Veterans Affairs, and the HHS Secretary’s Advisory Committee on Genomics, Health and Society. His work formed the basis of the Genetic Information Nondiscrimination Act of 2008 (GINA).

Apr 09, 2018

John Anson, Paul Kenny

Oxford Gene Technology has announced that it has appointed John Anson as CEO, who previously served as executive VP of research and development. He will be replacing Mike Evans, who has become a non-executive director of OGT's board 

In addition, OGT has appointed Paul Kenny as executive VP of regulatory and medical affairs. Kenny previously served as head of regulatory affairs at The Binding Site. 

Apr 03, 2018

Ronnie Andrews, Cavan Redmond

OncoCyte has appointed Ronald Andrews to its board of directors, bringing its total number of directors to seven and its independent directors to four. Andrews has over 30 years' experience in the molecular diagnostics and genomics industries, and was founder and principal of the Bethesda Group, a company focused on helping organizations in the molecular diagnostics and genomics industries. Prior to founding Bethesda, he served as president of the Genetic Sciences Division at Thermo Fisher Scientific and president of the Medical Sciences Venture at Life Technologies. He was also CEO and segment leader of GE Molecular Diagnostics at Clarient from 2004 until 2012. Andrews currently serves on the board of directors of Insight Genetics, Orion Healthcare, and Oxford Immunotec.

OncoCyte also announced that Cavan Redmond has been appointed as chairman of its board of directors. He will be replacing Alfred Kinglsey, who will remain a director of the firm. Before his time at OncoCyte, Redmond previously served as CEO of WebMD. In addition, he has served as senior VP and group president at Pfizer. 

Apr 02, 2018

Melody Harris

Melody Harris has joined SomaLogic as chief legal officer. Most recently, she was vice president and chief counsel at Qualcomm Life, a digital health subsidiary of Qualcomm. Prior to that, Harris was general counsel at HealthyCircles. 

Mar 28, 2018

Jennifer Doudna

Jennifer Doudna has joined Synthego's advisory board. Doudna will advise Synthego on a variety of product, partnership, and business strategy initiatives in order to help direct the company's plans in the genome engineering space. Doudna joins former GlaxoSmithKline CEO and UnitedHealth Group Director Andrew Witty Director on the firm's advisory board.

Mar 22, 2018

Scott Sorensen

Human Longevity has announced that it has appointed Scott Sorensen as its Chief Technology Officer. Sorenson previously worked at Ancestry, where he served in multiple roles including director of engineering and culminating as CTO. In the 16 past years at Ancestry, Sorenson directed the development of scalable technology platforms and architecture in addition to creating processes for engineers and scientists to deliver solutions to clients effectively.

Mar 21, 2018

Grannum Sant

Exosome Diagnostics has appointed Grannum Sant as its head of medical affairs. Sant holds an appointment as Professor of Urology at Tufts University, where he has spent more than two decades. He has also served various leadership positions in research and professional societies, including a term as President of the New England Section of the American Urological Association.

Outside of academia, Sant worked as a pharma medical affairs and clinical development executive, serving as a vice president of medical affairs at both Sanofi-Aventis US, and at Genzyme. Most recently he was the medical affairs lead for OPKO Health.

Mar 20, 2018

Jennifer Lee, Vikram Jog

Fluidigm said in a filing with the US Securities and Exchange Commission that Jennifer Lee, the company's current vice president, controller, and principal accounting officer, is resigning as of March 29. Vikram Jog, Fluidigm's current chief financial officer, will serve as principal accounting officer in addition to his current role. Jog has served as Fluidigm's CFO since February 2008.

Mar 20, 2018

Elaine Mardis

Elaine Mardis has been named president-elect of the American Association for Cancer Research for 2018-19. Her appointment will start next month in conjunction with the AACR annual meeting in Chicago, and she will become AACR president in April of 2019. Mardis holds the Nationwide Foundation Endowed Chair of Genomic Medicine and is the co-executive director of the Institute for Genomic Medicine at Nationwide Children's Hospital, and a professor of pediatrics at the Ohio State University College of Medicine. She holds a bachelor's degree and a PhD from the University of Oklahoma.  

Mar 20, 2018

Aaron Mendes, Debora Thompson, Sharon Terry

Luna DNA has hired Aaron Mendes as vice president of marketing and Debora Thompson as VP of business strategy and operation. The genomic and medical research database company also named Genetic Alliance CEO Sharon Terry to its advisory board. Thompson is a former director of market strategy and innovation for clinincal genomics at Illumina. Mendes is an entrepreneur who founded and later sold digital marketing intelligence startup Quantio. 

Mar 20, 2018

Mark Stenhouse

Exact Sciences has appointed Mark Stenhouse to the new role of president for its flagship product Cologuard, a non-invasive stool-based DNA test for early detection of colorectal cancer. Stenhouse, who is currently serving as vice president of the US immunology group at AbbVie, will assume this new position on April 2. At AbbVie, Stenhouse leads the sales and marketing teams for the anti-inflammatory drug Humira. He has spent nearly 30 years at Abbott Laboratories/AbbVie, where he was first hired for a field sales position. He became national sales director in the US immunology-gastroenterology franchise, and rose to marketing director, followed by senior director of commercial initiatives. In 2010, Stenhouse was appointed a general manager within the company before being promoted to vice president.

Mar 20, 2018

George Cardoza, Sharon Virag

NeoGenomics announced the appointments of George Cardoza as president of the Pharma Services Division, and Sharon Virag as chief financial officer. The position of president of the Pharma Services Division is a newly created position. Cardoza, who has served as chief financial officer since 2009, will lead a division that grew revenues 69 percent to $8.7 million last year. The division also includes a new lab in Rolle, Switzerland that was added last year to meet Pharma Services demand. Virag, who is succeeding Cardoza in the chief financial officer role, was previously vice president, corporate finance and chief accounting officer, at Aetna. Her appointment is effective March 27.

Mar 16, 2018

Gerald Herman

Bruker has appointed Gerald Herman as interim CFO effective March 17. Herman was also recently appointed as principal accounting officer for the company, and he will assume his additional responsibilities as interim CFO following the departure of current CFO Anthony Mattacchione, whose resignation was announced in February. Herman joined the company in 2016 as vice president and corporate controller. Prior to that, he held senior executive positions with various publicly traded companies including Parexel International and Presstek.

Mar 12, 2018

Phil Febbo

Illumina has appointed Phil Febbo as chief medical officer. Starting March 26, 2018, Febbo will be responsible for developing and executing on Illumina's strategy to drive genomic testing into healthcare practice.

Prior to Joining Illumina, Febbo has served as CMO at Genomic Health, and before that he served as professor of medicine and urology at the University of California, San Francisco, where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer. While at UCSF, Febbo was the co-leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology. He holds a BA degree in biology from Dartmouth College, received his MD at UCSF, and completed his internal medicine residency at the Brigham and Women's Hospital. 

Mar 12, 2018

Rob Brainin, Hannes Smàrason

Rob Brainin has been appointed as WuXi NextCode's CEO, replacing Hannes Smàrason, who will stay on as a senior advisor and plans to pursue other entrepreneurial opportunities. Most recently, Brainin was the firm's executive vice president and COO. Prior to that, he held positions at Illumina, Thermo Fisher, Life Technologies, and Invitrogen. Brainin holds a degree in economics from Emory University and a JD degree from Harvard Law School.

Mar 08, 2018

Arne Materna

CosmosID announced today that it appointed Arne Materna as its VP of product. Materna previously worked at Qiagen, where he directed the product management organization responsible for a high-growth segment of Qiagen's portfolio of bioinformatics products. Prior to Qiage, Materna held managment and senior roles at CLC bio, Pacific Biosciences, and MIT. 

Mar 07, 2018

David Cameron

Former UK prime minister David Cameron became a consultant for Illumina last month in order to help the company raise awareness about the benefits of genomics. Prior to his appointment, Cameron told the UK's Advisory Committee on Business Appointments that his main role would be to assist Illumina's engagement with foreign governments and stakeholders as it works and expands outside the UK, and that he would help with the formation of a new international advisory board and chair that board, which has not been established yet.

Mar 07, 2018

John Mattick

Genomics England has appointed John Mattick as its first CEO. Mattick will join Genomics England in June from Australia's Garvan Institute of Medical Research, which he has led since 2012. Mattick is noted for his scientific contributions to understanding the human genome, specifically his work showing that most of the genome is not evolutionary 'junk' but instead is devoted to an extensive RNA regulatory system that organizes human development. He will continue his academic career while in the UK at the University of Oxford's Green Templeton College, where he has been elected to a senior research fellowship for one day a week.

Mar 07, 2018

Paul Limburg

Exact Sciences has appointed Paul Limburg as co-chief medical officer. Limburg is a gastroenterologist and a professor of medicine at the Mayo Clinic, and serves as a co-leader of the Cancer Prevention and Control program within the Mayo Clinic Cancer Center. While at Mayo, he has also served as medical director of its global business solutions unit, and as medical director of several of its health and well-being programs. Limburg will advise Exact Sciences on research opportunities to inform, expand, and accelerate the adoption of effective colon cancer screening options such as Cologuard. He will continue to serve as a gastroenterologist with Mayo Clinic's Division of Gastroenterology and Hepatology, co-leader of the Cancer Prevention and Control program within Mayo Clinic Cancer Center, and principal investigator for the NCI-funded cancer prevention network clinical trials consortium.

Mar 02, 2018

Kim Albizati

Molecular Assemblies has appointed Kim Albizati as VP of chemistry and biochemistry. Prior to Molecular Assemblies, Albizati served senior direcctor of chemistry, manufactoring, and controls at Dart Neuroscience. In addition, Albizati has served as executive director of chemistry at Agouron and leadership positions at Pfizer. 

Pages

York University researchers find genomic evidence of inbreeding in the yellow-banded bumblebee, according to Reuters.

In its survey of US adults, the Pew Research Center finds that views on the genetic engineering of animals depend on why it's done.

The Scientist reports agricultural researchers are working on a gene-stacking tool.

In Nature this week: statistical method for overcoming case-control imbalance issues, and more.